Olema Pharmaceuticals

Update in progress

OLMA (NasdaqGS)

Olema Pharmaceuticals, Inc. is a clinical-stage biopharma focused on therapies for women’s cancers. Its lead candidate, palazestrant, is an estrogen receptor antagonist/degrader in Phase 3 for ER+/HER2- breast cancer, with trials such as OPERA-01, including monotherapy and combinations with CDK4/6 inhibitors and other agents. It also develops OP-3136, a KAT6 inhibitor, in Phase 1. Formerly CombiThera, it was renamed in 2009. Founded 2006, based in San Francisco.